65th ASH Annual Meeting & Exposition: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeted Therapy in Lymphoid Leukemias

Symposia: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms Oral and Poster Abstracts
Oral

Research, Lymphoid Leukemias, ALL, Translational Research, CLL, Lymphomas, non-Hodgkin lymphoma, Non-Biological therapies, drug development, Diseases, Therapies, Lymphoid Malignancies

Grand Hall B (Manchester Grand Hyatt San Diego)

Moderators:

Alejandro Gutierrez, MD, The Children's Hospital Corporation and Richard B. Lock, PhD, Children's Cancer Inst. Australia Lowy Cancer Research Centre, Univ N.S.W.

Disclosures:

No relevant conflicts of interest to declare.

9:30 AM

415

Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers

Thomas E Lew, MBBS^1,2^*, Mark Van Delft, PhD²^*, Chris Riffkin²^*, Georgiou Angela, Assoc Dip App Sci²^*, Christine White, BSc (Hons), PhD²^*, Yin Yuan, MBBS³, Jahja Michelle, BMedSci²^*, Mary Ann Anderson, MBBS, PhD, FRACP, FRCPA^1,2^*, Rachel Thijssen, PhD^2,4,5^*, David C.S. Huang, MBBS, PhD, MRCP²^*, Mark A. Dawson, MBBS, PhD, FRACP, FRCPA⁶ and Andrew W. Roberts, MBBS, PhD^7,8

¹Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
²The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
³The Walter and Eliza Hall Institute of Medical Research, North Melbourne, Vic, Australia
⁴Cancer Centre Amsterdam, Amsterdam, Netherlands
⁵Amsterdam UMC, Amsterdam, Netherlands
⁶Peter Maccallum Cancer Centre, Melbourne, VIC, Australia
⁷The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
⁸Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

9:45 AM

416

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4^th Generation BTK Inhibitor LP-168

Britten Gordon, BS¹, Elizabeth Muhowski, PhD²^*, Janani Ravikrishnan, PhD³^*, Samon Benrashid, BS¹^*, Andrew Mitchell, BS¹^*, Alexander He, BS¹^*, Shrilekha Misra, PhD¹^*, Tzung-Huei Lai, PhD¹^*, Shanmugapriya Thangavadivel, PhD⁴^*, Alexander Marr, BS¹^*, Lianbo Yu, PhD¹^*, Brandi Walker, BS¹^*, Elizabeth Perry, BS¹^*, Kerry A Rogers, MD⁴, Adam S Kittai, MD⁴, Seema A Bhat, MD³, John C. Byrd, MD⁵, Deepa Sampath, PhD⁶, Rosa Lapalombella, PhD¹, Weiguo Han, PhD⁷^*, Neil E. Kay, MD⁷, Yi Chen, PhD⁸^*, Fenlai Tan, MD, PhD⁹, Stephen P. Anthony, DO⁸, Yu Chen, MD, PhD⁸ and Jennifer A. Woyach, MD³

¹The Ohio State University, Columbus, OH
²Comprehensive Cancer Center, The Ohio State University, Columbus, OH
³The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁴Division of Hematology, The Ohio State University, Columbus, OH
⁵Department of Internal Medicine, University of Cincinnati, Cincinnati, OH
⁶MD Anderson Cancer Center, Houston, TX
⁷Division of Hematology, Mayo Clinic, Rochester, MN
⁸Newave Pharmaceutical Inc., Pleasanton, CA
⁹Guangzhou Lupeng Pharmaceutical Co. Ltd, Guangzhou, China

10:00 AM

417

Phenotypic Drug Response Profiling Identifies Asparaginase-Based Synergistic Combinations for Very High Risk Acute Lymphoblastic Leukaemia

Jasmeet Sidhu, MD^1,2,3^*, Fabio D. Steffen, PhD⁴^*, Iria Anne Jimenez³^*, Yun Huang³^*, Kerstin K. Rauwolf³^*, Arijit Chakraborty⁵^*, Shekhar Krishnan^1,2,6^*, Vaskar Saha, PhD, FRCP, FRCPath^1,2,6^*, Beat Bornhauser, PhD⁴^* and Jean-Pierre Bourquin, MD, PhD⁷

¹Tata Translational Cancer Research Center, Tata Medical Center, Kolkata, India
²Department of Paediatric Haematology and Oncology, Tata Medical Center, Kolkata, India
³University Children’s Hospital, Zurich, Switzerland
⁴Department of Oncology, University Children's Hospital Zurich, Zurich, Switzerland
⁵Tata Translational Cancer Research Center, Kolkata, India
⁶Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health,, University of Manchester, Manchester, United Kingdom
⁷Department of Oncology and Children’s Research Center, University Children's Hospital Zurich, Zurich, Switzerland

10:15 AM

418

Computational Discovery and Validation of NAD+ Biosynthesis As Unique Vulnerability in B-Lymphoid Malignancies

Qin Li, PhD¹^*, Mark E Robinson, PhD¹^*, Etienne Leveille, MD-PhD¹^*, Chang Zhang, PhD¹^*, Ruifeng Sun¹^*, Zhangliang Cheng¹^*, Kohei Kume, PhD¹^*, Kadriye Nehir Cosgun, PhD¹^*, Shalin Kothari, MD¹^*, Dhruv Khanduja¹^*, Daisuke Nakada, PhD² and Markus Müschen, MD¹

¹Center of Molecular and Cellular Oncology, Yale University, New Haven, CT
²Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX

10:30 AM

419

RPT1G: A 1^st-in-Class Small Molecule NAMPT Inhibitor As a Novel Therapeutic for Acute Lymphocytic Leukemia

Gregory Crimmins, PhD^*, Yushma Bhurruth-Alcor, PhD^*, Timothy Jarvela, PhD^*, Min Wu, PhD^*, Caroline M. Robb, PhD^*, James Digel, BS^*, Parisa Moghaddam-Taaheri, PhD^* and Dennise A. De Jesús-Díaz, PhD^*

Remedy Plan Therapeutics, Gaithersburg, MD

10:45 AM

420

The Transcription Factors NFATc1 and NFATc2 Control Glucocorticoid Resistance in Pediatric T-Cell Acute Lymphoblastic Leukemia

Giulia Veltri, PhD^1,2^*, Alberto Peloso^1,2^*, Alice Cani, PhD³^*, Elena Mariotto^1,2^*, Giulia Borile, PhD³^*, Loris Russo⁴^*, Chiara Frasson^1,2^*, Matilde Cescon⁴^*, Egidio Iorio⁵^*, Sonia Minuzzo⁶^*, Panagiotis Ntziachristos, PhD⁷, Alessandra Biffi, MD, PhD^1,8^*, Barbara Buldini, MD, PhD^1,9, Martina Pigazzi, PhD^3,8^*, Stefano Indraccolo, MD^6,10^*, Silvia Bresolin, PhD^1,2^* and Valentina Serafin, PhD¹

¹Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy
²Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova – Italy, University of Padua, Padova, Italy
³Foundation Istituto Ricerca Pediatrica (IRP), Padova, Italy
⁴Department of Molecular Medicine, University of Padova, Padova – Italy, University of Padua, Padova, Italy
⁵High Resolution NMR Unit Core Facilities, Istituto Superiore Di Sanità, Roma, Italy, Roma, Italy
⁶Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padova, Italy
⁷Ghent University, Corneel Heymanslaan 10, Ghent, Belgium
⁸Department of Women's and Children's Health, Onco-hematology lab and clinic, University of Padova, Padova, Italy
⁹Department of Pediatric Hematology and Oncology, University of Padova, Padua, Italy
¹⁰Istituto Oncologico Veneto - IRCCS, Padua, PD, ITA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

605.O2.6 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeted Therapy in Lymphoid Leukemias